Table 2.
Effect of transplant and patient characteristics on 25(OH)D concentrations*
| All | Children / Adolescents | Young Adults / Adults | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n (%) | Mean 25(OH)D nmol/L (95% CI) |
p | n (%) | Mean 25(OH)D nmol/L (95% CI) |
p | n (%) | Mean 25(OH)D nmol/L (95% CI) |
p | |
| Sex | |||||||||
| Female | 41 (43%) | 86.0 (76.5–96.8) | 0.23 | 18 (41%) | 92.5 (81.2–105.5) | 0.05 | 23 (45%) | 80.8 (67.5–96.8) | 0.81 |
| Male | 54 (57%) | 78.3 (70.5–86.8) | 26 (59%) | 78.2 (70.2–87.2) | 28 (55%) | 78.5 (66.5–92.5) | |||
| Years since transplant | |||||||||
| 1–1.9 | 23 (24%) | 75.3 (64.3–88.0) | 0.33 | 10 (23%) | 79.2 (65.8–95.2) | 0.68 | 13 (25%) | 74.8 (58.5–95.8) | 0.72 |
| 2–4.9 | 46 (48%) | 86.3 (77.3–96.5) | 24 (55%) | 86.0 (76.2–96.8) | 22 (43%) | 84.0 (69.8–101.2) | |||
| ≥ 5 | 26 (27%) | 79.0 (68.0–91.8) | 10 (23%) | 83.5 (69.2–100.8) | 16 (31%) | 77.5 (62.2–96.2) | |||
| Type of transplant | |||||||||
| Autologous | 12 (13%) | 77.0 (61.5–96.0) | 0.59 | 3 (7%) | 61.0 (44.2–84.5) | 0.05 | 9 (18%) | 82.8 (61.5–111.5) | 0.77 |
| Allogeneic | 83 (87%) | 82.0 (75.5–89.3) | 41 (93%) | 85.8 (78.8–93.5) | 42 (82%) | 78.8 (69.0–90.0) | |||
| Conditioning regimen | |||||||||
| Myeloablative | 70 (74%) | 78.5 (71.8–86.0) | 0.15 | 41 (93%) | 83.2 (76.0–91.0) | 0.53 | 29 (58%) | 69.5 (59.8–80.8) | 0.01 |
| Non-myeloablative | 24 (26%) | 89.5 (76.8–104.5) | 3 (7%) | 92.8 (66.2–129.8) | 21 (42%) | 94.5 (79.0–112.8) | |||
| History of acute GVHD | |||||||||
| no | 53 (56%) | 84.5 (76.0–93.8) | 0.31 | 27 (61%) | 85.0 (76.0–95.0) | 0.69 | 26 (51%) | 82.5 (69.8–97.8) | 0.53 |
| yes | 42 (44%) | 77.8 (69.3–86.8) | 17 (39%) | 82.0 (71.2–94.2) | 25 (49%) | 76.5 (64.2–90.8) | |||
| History of chronic GVHD | |||||||||
| no | 54 (57%) | 85.0 (76.8–94.5) | 0.22 | 36 (82%) | 86.2 (78.5–95.0) | 0.19 | 18 (35%) | 75.0 (61.0–91.8) | 0.47 |
| yes | 41 (43%) | 77.0 (68.3–86.8) | 6 (18%) | 73.5 (59.0–91.2) | 33 (65%) | 82.0 (70.8–95.2) | |||
| Currently on immunosuppression | |||||||||
| no | 71 (74%) | 87.0 (79.8–94.8) | 0.004 | 40 (91%) | 85.0 (77.5–93.0) | 0.35 | 31 (61%) | 86.0 (74.0–100.0) | 0.10 |
| yes | 24 (25%) | 67.3 (57.8–78.0) | 4 (9%) | 73.2 (54.5–99.0) | 20 (39%) | 70.2 (58.2–84.8) | |||
| Currently on prednisone | |||||||||
| no | 76 (80%) | 86.5 (79.8–94.0) | 0.002 | 43 (98%) | 83.8 (76.8–91.5) | 0.97 | 33 (65%) | 86.5 (74.8–100.0) | 0.06 |
| yes | 19 (20%) | 64.0 (54.3–75.5) | 1 (2%) | 82.8 (45.2–151.8) | 18 (35%) | 68.0 (56.0–83.0) | |||
| Vitamin D supplement use | |||||||||
| no | 37 (39%) | 65.3 (57.3–74.0) | <0.001 | 26 (59%) | 65.2 (57.2–74.0) | <0.001 | 11 (22%) | 65.2 (57.2–74.0) | <0.001 |
| yes | 58 (61%) | 94.0 (84.8–104.0) | 18 (41%) | 94.0 (84.8–104.0) | 40 (78%) | 94.0 (84.8–104.0) | |||
| Current weight category† | |||||||||
| underweight / normal weight | 25 (67%) | 85.2 (75.8–95.8) | 0.54 | 22 (48%) | 91.5 (76.8–109.2) | 0.04 | |||
| overweight / obese | 12 (32%) | 79.8 (67.2–94.8) | 24 (52%) | 71.0 (60.0–84.2) | |||||
Abbreviations: BMI = body mass index, CI = confidence interval, GVHD = graft-vs-host disease, kg = kilograms, L = liters, m = meters, nmol = nanomoles.
*
Geometric means, adjusted for total vitamin D intake, except for vitamin D supplement and total vitamin D intake stratifications.
†
According to Centers for Disease Control categorizations using sex-specific BMI-for-age for children and adolescents (2 – 19 years of age), and BMI for adults.